Skip to content

VITRO BIOPHARMA, INC.: 10-Q filed 2025-06-20

What VITRO BIOPHARMA, INC. reported in its quarterly report filed 2025-06-20 (fiscal Q2 2025): 44 published measures, 127 facts as tagged in accession 0001641172-25-015758.

This filing

Form
10-Q (quarterly report)
Filed
2025-06-20
Fiscal period
fiscal Q2 2025
Accession
0001641172-25-015758 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VITRO BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-04-304,575,227USD
At 2024-10-315,089,047USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-04-3015,640,680USD
At 2024-10-3114,090,020USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-04-30-11,065,453USD
At 2025-01-31-9,909,401USD
At 2024-10-31-9,000,973USD
At 2024-04-30-7,556,344USD
At 2024-01-31-4,825,792USD
At 2023-10-31-1,091,090USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-02-01 to 2025-04-30-1,478,786USD89
2024-11-01 to 2025-04-30-4,313,448USD181
2024-11-01 to 2025-01-31-2,834,662USD92
2024-02-01 to 2024-04-30-3,118,919USD90
2023-11-01 to 2024-04-30-7,688,105USD182
2023-11-01 to 2024-01-31-4,569,186USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-11-01 to 2025-04-30-1,118,703USD181
2023-11-01 to 2024-04-30-1,728,888USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-02-01 to 2025-04-30511,584USD89
2024-11-01 to 2025-04-30961,458USD181
2024-02-01 to 2024-04-30572,937USD90
2023-11-01 to 2024-04-30997,147USD182

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-02-01 to 2025-04-30511,584USD89
2024-11-01 to 2025-04-30961,458USD181
2024-02-01 to 2024-04-30572,937USD90
2023-11-01 to 2024-04-30997,147USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-11-01 to 2025-04-30748,199USD181
2023-11-01 to 2024-04-303,291,636USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-11-01 to 2025-04-30-2,781USD181
2023-11-01 to 2024-04-30-486USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-04-30-42,263,141USD
At 2024-10-31-37,949,693USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-02-01 to 2025-04-304,460,535shares89
2024-11-01 to 2025-04-304,460,535shares181
2024-02-01 to 2024-04-304,460,535shares90
2023-11-01 to 2024-04-304,457,898shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-02-01 to 2025-04-304,460,535shares89
2024-11-01 to 2025-04-304,460,535shares181
2024-02-01 to 2024-04-304,460,535shares90
2023-11-01 to 2024-04-304,457,898shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-02-01 to 2025-04-30-0.33USD/shares89
2024-11-01 to 2025-04-30-0.97USD/shares181
2024-02-01 to 2024-04-30-0.7USD/shares90
2023-11-01 to 2024-04-30-1.72USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-02-01 to 2025-04-30-0.33USD/shares89
2024-11-01 to 2025-04-30-0.97USD/shares181
2024-02-01 to 2024-04-30-0.7USD/shares90
2023-11-01 to 2024-04-30-1.72USD/shares182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-04-3077,584USD
At 2024-10-31139,552USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-02-01 to 2025-04-30322,734USD89
2024-11-01 to 2025-04-30730,968USD181
2024-02-01 to 2024-04-30388,367USD90
2023-11-01 to 2024-04-30772,851USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-02-01 to 2025-04-30-1,082,312USD89
2024-11-01 to 2025-04-30-2,927,830USD181
2024-02-01 to 2024-04-30-945,746USD90
2023-11-01 to 2024-04-30-5,820,550USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-04-30597,319USD
At 2024-10-31975,753USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-04-3013,904,747USD
At 2024-10-3110,062,688USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2025-04-303,171,581USD
At 2024-10-313,171,581USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-04-30342,846USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-04-30166,553USD
At 2024-10-31115,365USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-02-01 to 2025-04-30376,757USD89
2024-11-01 to 2025-04-30733,539USD181
2024-02-01 to 2024-04-30478,767USD90
2023-11-01 to 2024-04-30817,783USD182

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-02-01 to 2025-04-301,236,638USD89
2024-11-01 to 2025-04-303,365,055USD181
2024-02-01 to 2024-04-301,284,824USD90
2023-11-01 to 2024-04-303,685,447USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-02-01 to 2025-04-30222,431USD89
2024-11-01 to 2025-04-30296,314USD181
2024-02-01 to 2024-04-30139,689USD90
2023-11-01 to 2024-04-30295,924USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-04-304,460,535shares
At 2024-10-314,460,535shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-04-30198,075USD
At 2024-10-31571,360USD
At 2024-04-301,664,016USD
At 2023-10-31101,754USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-04-3031,277,228USD
At 2024-10-3129,028,260USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-04-30285,130USD
At 2024-10-31346,091USD
At 2023-05-31271,396USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-04-30285,130USD
At 2023-05-31271,396USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2025-04-3011,188,096USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-04-301,059,765USD
At 2024-10-311,059,765USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-04-30982,181USD
At 2024-10-31920,213USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-04-30342,846USD
At 2024-10-31358,084USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-04-308,438USD
At 2024-10-318,438USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-04-301,838,253USD
At 2024-10-311,806,419USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-02-01 to 2025-04-30-1,478,786USD89
2024-11-01 to 2025-04-30-4,313,448USD181
2024-02-01 to 2024-04-30-3,118,919USD90
2023-11-01 to 2024-04-30-7,688,105USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-02-01 to 2025-04-3024,534USD89
2024-11-01 to 2025-04-3061,968USD181
2024-02-01 to 2024-04-3048,241USD90
2023-11-01 to 2024-04-3091,785USD182

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-02-01 to 2025-04-307,619USD89
2024-11-01 to 2025-04-3015,238USD181
2024-02-01 to 2024-04-3016,948USD90
2023-11-01 to 2024-04-3033,896USD182

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-02-01 to 2025-04-30395,960USD89
2024-11-01 to 2025-04-30499,653USD181
2024-02-01 to 2024-04-302,160,299USD90
2023-11-01 to 2024-04-302,331,928USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-11-01 to 2025-04-304,872USD181
2023-11-01 to 2024-04-308,331USD182

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2024-11-01 to 2025-04-3081,515USD181
2023-11-01 to 2024-04-30108,248USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-11-01 to 2025-04-30-76,168USD181
2023-11-01 to 2024-04-3037,434USD182

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-11-01 to 2025-04-3051,188USD181
2023-11-01 to 2024-04-3010,942USD182

Inspect the source

Entity
VITRO BIOPHARMA, INC. / CIK 0000793171
Captured
2026-09-21T17:17:03.076Z
SEC response SHA-256
e4a45888e3fd56bf245fee78b2235f6f8d9c94b7a357b46c64ff1e0e8b6cac32

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000793171.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))